Small cohort studies have demonstrated more severe ILD (defined as greater extent of fibrosis on HRCT and impairment of pulmonary function measures), and greater resistance to immunosuppressive therapy in anti-Jo-1 positive myositis patients with concomitant anti-SSA/Ro antibodies compared with anti-SSA/Ro negative patients [119,120]. The gene discussed is TRIM21; the disease is myositis disease.